{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:23:42Z","timestamp":1793291022274,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.36321","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T06:29:22Z","timestamp":1612592962000},"page":"e2036321","source":"Crossref","is-referenced-by-count":98,"title":["Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults"],"prefix":"10.1001","volume":"4","author":[{"given":"Casey Lee","family":"McAtee","sequence":"first","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lubega","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Underbrink","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Texas Children\u2019s Hospital, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Barrow","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Muscal","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Lotze","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poyyapakkam","family":"Srivaths","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Allen","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brooke","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"6","key":"zoi201086r1","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","article-title":"Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children\u2019s hospitals across the United States.","volume":"162","author":"Kavcic","year":"2013","journal-title":"J Pediatr"},{"issue":"2","key":"zoi201086r2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"zoi201086r3","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience.","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"zoi201086r4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action.","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"6","key":"zoi201086r5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"issue":"6","key":"zoi201086r6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bjh.2005.129.issue-6","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"zoi201086r7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers7010305","article-title":"Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?","volume":"7","author":"Worch","year":"2015","journal-title":"Cancers (Basel)"},{"key":"zoi201086r8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpeds.2017.05.002","article-title":"Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review.","volume":"187","author":"Mahmoud","year":"2017","journal-title":"J Pediatr"},{"issue":"6","key":"zoi201086r9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"zoi201086r10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/infdis\/jiaa256","article-title":"High risk of clinical relapse in patients with chronic hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy.","volume":"222","author":"Chang","year":"2020","journal-title":"J Infect Dis"},{"issue":"4","key":"zoi201086r11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1177\/1078155219879496","article-title":"Development of pneumonitis after rituximab treatment in a patient with lymphoma.","volume":"26","author":"Mert","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"zoi201086r12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.","volume":"24","author":"Berger","year":"2018","journal-title":"J Neurovirol"},{"issue":"11","key":"zoi201086r13","doi-asserted-by":"publisher","first-page":"CS133","DOI":"10.12659\/MSM.882034","article-title":"Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis.","volume":"17","author":"Weissmann-Brenner","year":"2011","journal-title":"Med Sci Monit"},{"issue":"7","key":"zoi201086r14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia.","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi201086r16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2174\/1573396314666180507115115","article-title":"Anaphylaxis in children: epidemiology, risk factors and management.","volume":"14","author":"Anagnostou","year":"2018","journal-title":"Curr Pediatr Rev"},{"issue":"4","key":"zoi201086r17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study.","volume":"10","author":"Gill","year":"1982","journal-title":"Ann Statistics"},{"key":"zoi201086r18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1475-2875-13-293","article-title":"Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data.","volume":"13","author":"Sagara","year":"2014","journal-title":"Malar J"},{"issue":"1","key":"zoi201086r19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0895-4356(99)00137-7","article-title":"Analytic strategies for recurrent events in epidemiologic studies: background and application to hospitalization risk in the elderly.","volume":"53","author":"St\u00fcrmer","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"zoi201086r21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"zoi201086r23","author":"Bates","journal-title":"J Stat Software"},{"issue":"9950","key":"zoi201086r25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"zoi201086r26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab.","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"issue":"46","key":"zoi201086r27","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea.","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"zoi201086r28","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"zoi201086r29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/rheumatology\/key306","article-title":"Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"zoi201086r30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome.","volume":"25","author":"Prytula","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"zoi201086r31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2169\/internalmedicine.53.1342","article-title":"Incidence of malignancies in patients with IgG4-related disease.","volume":"53","author":"Hirano","year":"2014","journal-title":"Intern Med"},{"issue":"3","key":"zoi201086r32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi201086r33","first-page":"112","article-title":"Malignancies after rituximab treatment: just coincidence or more?","volume":"16","author":"Aksoy","year":"2011","journal-title":"J BUON"},{"issue":"7","key":"zoi201086r34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi201086r35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3899\/jrheum.140863","article-title":"Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.","volume":"42","author":"Tambralli","year":"2015","journal-title":"J Rheumatol"},{"issue":"2-3","key":"zoi201086r36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2014a review of the literature.","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"zoi201086r37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia.","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"issue":"5","key":"zoi201086r38","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis.","volume":"27","author":"Raanani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi201086r39","first-page":"273","article-title":"Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.","volume":"12","author":"Bass","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"zoi201086r40","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3389\/fimmu.2018.01925","article-title":"Limited innovations after more than 65 years of immunoglobulin replacement therapy: potential of IgA- and IgM-enriched formulations to prevent bacterial respiratory tract infections.","volume":"9","author":"Langereis","year":"2018","journal-title":"Front Immunol"},{"key":"zoi201086r41","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fimmu.2017.01056","article-title":"Selective IgM deficiency\u2014an underestimated primary immunodeficiency.","volume":"8","author":"Gupta","year":"2017","journal-title":"Front Immunol"},{"issue":"14","key":"zoi201086r42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/imt-2018-0074","article-title":"Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.","volume":"10","author":"Ochs","year":"2018","journal-title":"Immunotherapy"},{"issue":"8","key":"zoi201086r43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/acr2.v1.8","article-title":"Patterns of B cell repletion following rituximab therapy in a pediatric rheumatology cohort.","volume":"1","author":"Mitchell","year":"2019","journal-title":"ACR Open Rheumatol"},{"issue":"10","key":"zoi201086r44","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.4049\/jimmunol.1004095","article-title":"Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens.","volume":"186","author":"Bedognetti","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"zoi201086r45","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi201086r46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.v62:1","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"zoi201086r20","volume-title":"Categorical Data Analysis","author":"Agresti","year":"2013","edition":"3rd ed"},{"key":"zoi201086r15","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Published November 27, 2017. Accessed January 17, 2020. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"zoi201086r22","unstructured":"Therneau? TM. survival: Survival Analysis. Accessed January 14, 2021. https:\/\/CRAN.R-project.org\/package=survival"},{"key":"zoi201086r24","unstructured":"R Core Team. The R project for statistical computing. Updated November 2, 2020. Accessed December 20, 2020. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2775825\/mcatee_2021_oi_201086_1614014610.79044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T11:27:03Z","timestamp":1614598023000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2775825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36321","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}